Browse by ▼

AbbVie Inc.

  • Watch This HCV Player

    By Brandy Betz - May 22, 2013 | Tickers: ABBV, GILD, JNJ

    Johnson & Johnson's (NYSE: JNJ) hepatitis C drug, simeprevir, recently received Priority Review status from the FDA. It was a surprising validation for Johnson's mid-stage project. But there are stronger candidates from Gilead (NASDAQ: GILD) and Abbvie (NYSE: ABBV) further ahead in the pipes.

    Simeprevir does have a trick up its sleeve. The drug could offer near perfect efficacy when used in combo therapies -- if the right company agrees more »

  • Should We Follow Dodge & Cox's 2 New Buys?

    By Anh HOANG - May 20, 2013 | Tickers: ABBV, KRFT, MDLZ

    Dodge & Cox is famous for its outstanding performance, delivering an annualized return of 12.5%, beating the S&P 500’s annualized return of 10.8% for the past 30 years. Founded in 1930, Dodge & Cox is currently managing around $84 billion in its long portfolio. In the first quarter of 2013, Dodge & Cox initiated long positions in Kraft Foods (NASDAQ: KRFT) and AbbVie (NYSE: ABBV). Let’s take a more »

  • A Quick Look at Avalon Advisor’s Big Buys Last Quarter

    By Aubrey Tabuga - May 17, 2013 | Tickers: ABBV, FITB, JNJ, TXN, DOW

    The 5 big buys of Avalon Advisors in the first quarter of 2013 are AbbVie (NYSE: ABBV), The Dow Chemical Company (NYSE: DOW), Texas Instruments (NASDAQ: TXN), Johnson & Johnson (NYSE: JNJ), and Fifth Third Bancorp (NASDAQ: FITB). Avalon Advisors is one of Houston’s largest money management firms. Based on whalewisdom.com compilation, the firm had over $1.646 billion in assets under management as of the end of the more »

  • Insights From CI Investments’ Five Big Buys

    By Aubrey Tabuga - May 16, 2013 | Tickers: ABBV, BAX, CVX, C, OXY

    CI Investments has recently won seven 2013 Lipper Fund Awards for its strong risk-adjusted returns relative to its peers. I looked into its first quarter big buys from a fundamental lens to provide investment insights. These are AbbVie (NYSE: ABBV), Baxter (NYSE: BAX), Chevron (NYSE: CVX), Occidental Petroleum (NYSE: OXY), and Citigroup (NYSE: C).

    Interestingly, these stocks have all posted positive earnings surprises, have P/E ratios not higher than more »

  • Don’t Make Investing Too Complicated

    By Matthew Luke - May 10, 2013 | Tickers: ABT, ABBV, BEAM, CHD, MCD

    If I could send a message back in time to my younger self, I would only need to use four words, “Keep it simple, Stupid!” This is great advice for life in general, but especially good advice when investing one’s own money. How much better would my stock portfolio would look today if I had realized this when I first began investing!

    Sometimes we as investors can fall into more »

  • This New Drug Maker Still Has Upside Potential Left

    By Nick Chiu - May 9, 2013 | Tickers: ABT, ABBV, PFE

    AbbVie (NYSE: ABBV), formed in January this year following separation from Abbott Laboratories (NYSE: ABT), is a global, research-based pharmaceutical company with strong exposure to the immunology and cardiovascular diseases market.

    By spinning off its research-based pharmaceutical business, Abbott, a large-cap diversified healthcare company, now operates in four segments: diagnostics, medical devices, nutritionals, and generic pharmaceuticals. The nutrition segment is the main growth driver for Abbott, with a compound annual more »

  • Are These Spin-Offs Investment Worthy?

    By Robert Ciura - May 6, 2013 | Tickers: ABT, ABBV, COP, PSX

    There have been a number of high-profile spin-offs over the past few years. Spin-offs, a form of divestiture in which a company will separate a subsidiary to form a separate and independent company, might catch investors by surprise. However, the newly separated businesses are often more rapidly growing than their former parent companies.

    Investors of the parent company receive shares in the spun-off businesses automatically, but as separate entities these more »

  • Building a Stronger Core With Abbott Laboratories

    By Justin Carley - April 30, 2013 | Tickers: ABT, ABBV, MJN, MDT, RHHBY

    It has been more than a 100 days since Abbott Laboratories (NYSE: ABT) separated its research-based pharmaceutical business into a newly formed entity named AbbVie (NYSE: ABBV). As is often the case, the spin-off has been the initial winner. AbbVie has produced a total return of more than 32% in pretty quick order. Abbott has done well, but the 17% return has clearly not kept pace. AbbVie is now a more »

  • 5 Stocks With 40 or More Years of Dividend Increases

    By Meena Krishnamsetty - April 30, 2013 | Tickers: ABBV, KMB, MSEX, PEP, VFC

    Market-beating strategies are inherently hard to find. Based on the evidence from several major developed markets, dividend growth was the single largest contributor to nominal stock market returns over the past 40 years, according to Société Générale.

    An exclusive club

    A small group of companies pursues a policy of boosting shareholder value through consistent annual dividend increases for decades. Among the stocks with the longest streaks of consecutive dividend growth more »

  • Is The Risk Worth The Large Potential Reward?

    By Mike Thiessen - April 29, 2013 | Tickers: ABBV, AUXL, LLY

    Auxilium Pharmaceuticals (NASDAQ: AUXL) stock has a lot of negative sentiment priced into the shares, maybe too much at this point. Often when the Street has bearish outlook on a stock, interest in it falls off and the shares overshoot fair value. This can create opportunities for investor.

    Auxilium is a biopharmaceutical company that develops and markets products to two specialized markets. The company currently markets Testim testosterone gel and more »

  • Three Stocks to Profit from Zombie Apocalypse Thinking

    By AnnaLisa Kraft - April 29, 2013 | Tickers: ABBV, KRFT, ZTS

    The rationale behind the popularity of  doomsday zombie scenarios is that the future is so bleak even zombies come as a welcome alternative. That's the theory of author, Doug Rushkoff, whose "Present Shock" details the hurry up world that is traumatizing us.

    One example of his was the Facebook IPO. People expected to make immediate bucks and when they didn't they fled the stock. "When everything happens now more »

  • Which One Should Investors Buy: The Ex-Parent or the Spin-off?

    By Anh HOANG - April 24, 2013 | Tickers: ABT, ABBV, TEVA

    Tom Russo, a partner at Gardner Russo & Gardner, has managed to deliver a 13.2% annualized return for the past 25 years, beating the S&P 500’s annualized return of 9.7%. As of March 2013, he had more than $8.5 billion in total assets under management with around 255 stocks in his portfolio.

    In the first quarter of 2013, he purchased 88,250 shares in AbbVie (NYSE: ABBVmore »)

  • Alzheimer’s Milkshakes and the Growth of Medical Nutrition

    By Matthew Luke - April 22, 2013 | Tickers: ABT, ABBV, BMY, DANOY.PK, MJN, NSRGY, PFE

    A milkshake is not foremost on most people’s list of treatments for the neurological disorder Alzheimer’s. But a milkshake is indeed one treatment for those with early-stage Alzheimer’s disease, thanks to the recent United Kingdom release of Souvenaid. This milkshake and similar products are some of the many treatment options in an emerging hybridization of food and medicine.

    Defining a Milkshake
    By “milkshake” I of course do more »

  • 1 Pharma Stock to Buy, 1 to Sell

    By Masam Abbas - April 16, 2013 | Tickers: ABBV, BDX, JNJ

    The earnings season for pharmaceutical stocks will be kicked off by Johnson & Johnson (NYSE: JNJ) on April 16. Let’s have a look at the earnings preview of two important stocks in this space to see what this industry holds for the market:

    AbbVie Inc. (NYSE: ABBV)

    AbbVie is expected to announce its quarterly results on April 26. The company is expected to post an EPS of $0.66 and more »

  • 1 Pharma Stock to Buy, 1 to Sell

    By Masam Abbas - April 16, 2013 | Tickers: ABBV, BDX, JNJ

    The earnings season for pharmaceutical stocks will be kicked off by Johnson & Johnson (NYSE: JNJ) on April 16. Let’s have a look at the earnings preview of two important stocks in this space to see what this industry holds for the market:

    AbbVie Inc. (NYSE: ABBV)

    AbbVie is expected to announce its quarterly results on April 26. The company is expected to post an EPS of $0.66 and more »

  • 1 Pharma Stock to Buy, 1 to Sell

    By Masam Abbas - April 14, 2013 | Tickers: ABBV, BDX, JNJ

    The earnings season for Pharma stocks is expected to be kicked off by Johnson & Johnson on April 16. Let’s have a look at the earnings preview of two important stocks in this space to see what this industry holds for the market:

    AbbVie Inc. (NYSE: ABBV)

    The forecast for 1QQ13

    The company is expected to announce its quarterly results on April 26. The company is expected to post an more »

  • 3 Attractive Healthcare Dividend Stocks

    By Mohsin Saeed - March 29, 2013 | Tickers: ABBV, AZN, PETS

    The government has been trying to jump start our economy with low interest rates and other methods of quantitative easing. While these methods are imperative for improving the economy, they also reduce the attractiveness of interest-based instruments. This has made dividend stocks particularly attractive over the last couple of years.The following three healthcare companies offer pretty high dividends and fundamentals show that these dividends are sustainable.

    AbbVie (NYSE: ABBVmore »)

  • How Safe is AbbVie from Niacin’s Woes?

    By Shas Dey - March 21, 2013 | Tickers: ABBV, BIIB, MRK, NBIX

    Niacin is a B vitamin essential for the normal function of the nervous system and the gastrointestinal tract, and used for boosting high density lipoprotein (HDL), the “good cholesterol." Although OTC versions of Niacin are available as daily vitamin supplements, a prescription form called Niaspan from AbbVie Inc. (NYSE: ABBV) is a widely prescribed drug for heart patients. However, recent developments do not look too good for the drug.

    More more »

  • Interesting Medical Spin-Off for Mid-2013

    By Mike Thiessen - March 18, 2013 | Tickers: ABBV, COV, TYC

    Dublin-based medical conglomerate Covidien PLC (NYSE: COV) has confirmed that it plans to complete the spin-off of its pharmaceutical division by the middle of 2013. Although the proposal to create Mallinckrodt Pharmaceuticals was announced more than a year ago, it has been subject to some non-fatal delays along the way. However, these appear to have been resolved. The soon-to-be-independent division has embarked on a major hiring spree and appears poised more »

  • My Perfect Divided Portfolio - Summary and Update

    By Karin Hernandez - March 15, 2013 | Tickers: ABT, ABBV, EPD, LMT, MDP, PRE, SXL, WMB

    In December, I started building what I call my Perfect Dividend Portfolio – one company at a time, and analyzing each company using a rating system I developed myself.

    I review the stocks on seven different criteria; I feel that my selection covers the company’s past dividend-paying history, its potential future earnings growth, and the valuation of the company.

    The company must be yielding at least 3.0% annually, it more »

  • Page 1 of 2